450412-28-9

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-3-chloro-2-iodobenzene is used as a synthetic intermediate for the production of pharmaceuticals. Its unique structure allows it to be a key component in the creation of new drugs, contributing to the development of novel treatments and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Bromo-3-chloro-2-iodobenzene serves as an intermediate in the synthesis of agrochemicals. It plays a crucial role in developing compounds that protect crops from pests and diseases, thereby ensuring food security and agricultural productivity.
Used in Organic Material Synthesis:
1-Bromo-3-chloro-2-iodobenzene is utilized as a building block in the synthesis of organic materials. Its presence in these materials can enhance their properties, such as stability, reactivity, or specific chemical functionalities, making them suitable for various applications.
Used in Research and Development:
1-BROMO-3-CHLORO-2-IODOBENZENE is also used in research and development as a component in various chemical reactions, including halogenation and coupling reactions. Its participation in these reactions aids scientists in exploring new chemical pathways and discovering innovative applications in the chemical industry.
Overall, 1-Bromo-3-chloro-2-iodobenzene is a multifaceted chemical intermediate with applications spanning across different industries, highlighting its importance in the development of new products and chemical processes.

InChI:InChI=1/C6H3BrClI/c7-4-2-1-3-5(8)6(4)9/h1-3H

Upstream product

• 108-37-2 1-bromo-3-chlorobenzene 

Relevant academic research and scientific papers

Phosphorus-containing bicyclic compound and preparation method and application thereof

The invention belongs to the technical field of electroluminescent materials, and particularly relates to a phosphorus-containing bicyclic compound and a preparation method and application thereof. The phosphorus-containing bicyclic compound has the struc

LIGHT-EMITTING MATERIAL FOR ORGANIC ELECTROLUMINESCENT DEVICE, ORGANIC ELECTROLUMINESCENT DEVICE USING SAME, AND MATERIAL FOR ORGANIC ELECTROLUMINESCENT DEVICE

Disclosed are a novel aromatic compound having excellent light emitting efficiency and thermal stability, a manufacturing method thereof, and an organic electroluminescent device comprising the novel aromatic compound. According to the present invention, provided are an aromatic compound forming a ring, and a novel aromatic derivative represented by chemical formula 1, which improves performance of a device. In the chemical formula 1, Z is equally or differently N (nitrogen), O (oxygen), or S (sulfur) in each case. Also, when Z is N (nitrogen), L1 is an integer of 1, and when Z is O (oxygen) or S (sulfur), L1 is an integer of 0.COPYRIGHT KIPO 2015

Transition-metal-free atropo-selective synthesis of biaryl compounds based on arynes

A modular way towards biaryls: Highly enantioenriched biphenyls can be prepared based on a transition-metal-free aryl-aryl coupling followed by efficient desymmetrization or deracemization and chemoselective functionalization (see scheme). Copyright

Renin Inhibitors

Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Ring opening of aziridines with ortho-bromophenyl metal reagents: synthesis of 2-substituted indolines

Stabilized ortho-bromo phenyllithium reagents, generated via lithium-halogen exchange of aryl iodides, undergo regioselective ring opening of mono-substituted N-Boc, N-Cbz, and N-tosyl-protected aziridines in good to excellent yields. The resulting ortho-

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Disclosed are compounds of Formula I, wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration

Generation and suppression of 3-/4-functionalized benzynes using zinc ate base (TMP-Zn-ate): New approaches to multisubstituted benzenes

We present full details of our new methods for preparing functionalized benzynes with lithium di-alkyl(2,2,6,6-tetramethylpiperidino)zincate (R 2Zn(TMP)Li) through deprotonative zincation as a key reaction. In this system, by choosing appropriate ligands for the zincate, either regioselective zincation of functionalized haloaromatics or the generation of substituted benzynes can be controlled in good yields with excellent chemoselectivity, using the same substrate. Zincation with tBu 2Zn(TMP)Li followed by electrophilic trapping or zincation with Me2Zn(TMP)Li followed by nucleophilic or diene trapping is shown to be a powerful tool for the chemoselective preparation of 1,2,3-/1,2,4- trisubstituted benzene derivatives. These methods offer far greater generality than previous methods for the synthesis of multifunctionalized benzenes. Computational/theoretical studies of the reaction mechanism of this unique benzyne formation indicated that preferential coordination of the dialkylzinc moiety of zincate to halogen is the reason for the reduced activation energy of the elimination, that is, for the formation of the benzyne. The role of the ligands on Zn in accelerating/decelerating the elimination is also discussed.

PIPERIDINE AND MORPHOLINE RENIN INHIBITORS

Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.